

In the United States Patent and Trademark Office

Before the Patent Trial and Appeal Board

AMERIGEN PHARMACEUTICALS LIMITED,

Petitioner

v.

JANSSEN ONCOLOGY, INC.,

Patent Owner

U.S. Patent No. 8,822,438 to Auerbach *et al.*

Issue Date: September 2, 2014

Title: Methods and Compositions for Treating Cancer

Inter Partes Review No. Unassigned

Petition for *Inter Partes* Review of U.S. Patent No. 8,822,438 Under
35 U.S.C. §§ 311-319 and 37 C.F.R. §§ 42.1-42.80, 42.100-42.123

Mail Stop “PATENT BOARD”

Patent Trial and Appeal Board

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, Virginia 22313-1450

Submitted Electronically via the Patent Review Processing System

TABLE OF CONTENTS

TABLE OF CONTENTS	i
LISTING OF EXHIBITS PURSUANT TO 37 C.F.R. § 42.63(e) AND TABLE OF ABBREVIATIONS	iii
TABLE OF ABBREVIATIONS	x
CHALLENGED CLAIMS OF U.S. PATENT NO. 8,822,438	xi
I. INTRODUCTION	1
II. MANDATORY NOTICES (37 C.F.R. § 42.8(a)(1))	1
A. <i>Real Party-In-Interest Under 37 C.F.R. § 42.8(b)(1)</i>	1
B. <i>Related Matters Under 37 C.F.R. § 42.8(b)(2)</i>	1
C. <i>Lead And Back-Up Counsel Under 37 C.F.R. § 42.8(b)(3)</i>	2
D. <i>Service Information Under 37 C.F.R. § 42.8(b)(4)</i>	2
E. <i>Service on Patent Owner Under 37 C.F.R. § 42.106(a) and 42.105(a)</i>	2
III. GROUNDS FOR STANDING (37 C.F.R. §§ 42.101 and 42.104)	3
IV. PAYMENT OF FEES (37 C.F.R. § 42.103)	4
V. STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFOR (37 C.F.R. § 42.22(a))	4
VI. IDENTIFICATION OF CHALLENGE (37 C.F.R. § 42.104(b))	4
VII. INTRODUCTION AND SUMMARY OF ARGUMENT	5
VIII. LEVEL OF ORDINARY SKILL IN THE ART	7
IX. U.S. PATENT NO. 8,822,438 AND ITS FILE HISTORY	8
A. <i>Specification of the '438 Patent</i>	8
B. <i>File History of the '438 Patent</i>	11
X. CLAIM CONSTRUCTION (37 C.F.R. §§ 42.100(b), 42.104(b)(3))	17
XI. SCOPE AND CONTENT OF THE PRIOR ART	19
A. <i>Overview</i>	19
B. <i>Background of Prostate Cancer and Its Treatment</i>	23
C. <i>Prior Art References</i>	28
1. IN 2004, O'DONNELL DESCRIBED THE ADMINISTRATION OF ABIRATERONE ACETATE AS MORE EFFECTIVE FOR TREATING METASTATIC REFRACTORY PROSTATE CANCER THAN KETOCONAZOLE, AND POSSIBLY REQUIRING CONCOMITANT GLUCOCORTICOID REPLACEMENT THERAPY	28
2. IN 1990, GERBER DISCLOSED THE USE OF KETOCONAZOLE WITH PREDNISONE, A GLUCOCORTICOID, IN PATIENTS WITH HORMONE REFRACTORY METASTATIC PROSTATE CANCER	31

3.	IN 1997, THE '213 PATENT DISCLOSED ABIRATERONE ACETATE, AND ITS SUPERIORITY OVER KETOCONAZOLE IN THE TREATMENT OF PROSTATE CANCER	33
XII.	EXPLANATION OF GROUNDS FOR UNPATENTABILITY.....	36
A.	<i>Claim 1</i>	36
B.	<i>Claims 2 and 3</i>	40
C.	<i>Claim 4</i>	41
D.	<i>Claim 5</i>	42
E.	<i>Claims 6-9</i>	43
F.	<i>Claim 10</i>	44
G.	<i>Claim 11</i>	44
H.	<i>Claims 12-16</i>	45
I.	<i>Claim 17</i>	46
J.	<i>Claim 18</i>	47
K.	<i>Claim 19</i>	47
L.	<i>Claim 20</i>	48
XIII.	SECONDARY CONSIDERATIONS DO NOT INDICATE THAT THE CLAIMS OF THE '438 PATENT ARE NON-OBVIOUS	48
A.	<i>Applicants Did Not Offer Relevant Evidence of Commercial Success and the Examiner Issued the '438 Patent Based on the Erroneous Conclusion that the Asserted Commercial Success of Zytiga® Overcame the Obviousness of the Claimed Invention.</i>	48
B.	<i>One of Skill Would Not Anticipate Unexpected Benefits from the Claimed Invention and Applicants Did Not Offer Any Evidence of Relevant Unexpected Results</i>	52
C.	<i>The '438 Patent Satisfied No Long-Felt But Unmet Need</i>	56
D.	<i>The '213 is a Blocking Patent that Limits the Applicability of Commercial Success</i> ---	57
E.	<i>Copying By Generic Drug Makers Is Irrelevant</i>	59
XIV.	CONCLUSION	59
	CERTIFICATE OF SERVICE	60

**LISTING OF EXHIBITS PURSUANT TO 37 C.F.R. § 42.63(e) AND
TABLE OF ABBREVIATIONS**

Exhibit	Description
AMG 1001	U.S. Patent No. 8,822,438, Auerbach and Beldegrum, “Methods and Compositions for Treating Cancer” (“the ‘438 patent”)
AMG 1002	Declaration of Dr. Scott Serels, MD (“Serels Decl.”)
AMG 1003	O’Donnell, A. <i>et al.</i> , “Hormonal impact of the 17 α -hydroxylase/C ₁₇ -20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer,” <i>British Journal of Cancer</i> , (90):2317-2325 (2004) (“O’Donnell”)
AMG 1004	Gerber, G.S. <i>et al.</i> , “Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic cancer,” <i>The Journal of Urology</i> , 144(5):1177-9 (1990) (“Gerber”)
AMG 1005	U.S. Patent No. 5,604,213, Barrie S.E. <i>et al.</i> , “17-Substituted Steroids Useful In Cancer Treatment” (“the ‘213 patent”)
AMG 1006	Tannock <i>et al.</i> , “Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points,” <i>The Journal of Clinical Oncology</i> , 14:1756-1764 (1996) (“Tannock”)
AMG 1007	February 3, 2012 Office Action (excerpt from prosecution history of ‘438 patent)
AMG 1008	July 3, 2012 Response (excerpt from prosecution history of ‘438 patent)

AMG 1009	Ryan <i>et al.</i> , “Abiraterone in metastatic prostate cancer without previous chemotherapy,” <i>The New England Journal of Medicine</i> , 368:138-148 (2012).
AMG 1010	January 11, 2013 Response (excerpt from prosecution history of '438 patent)
AMG 1011	March 4, 2013 Office Action (excerpt from prosecution history of '438 patent)
AMG 1012	June 4, 2013 Response (excerpt from prosecution history of '438 patent)
AMG 1013	July 3, 2013 Notice of Allowance (excerpt from prosecution history of '438 patent)
AMG 1014	October 25, 2013 Notice of Allowance (excerpt from prosecution history of '438 patent)
AMG 1015	February 11, 2014 Notice of Allowance (excerpt from prosecution history of '438 patent)
AMG 1016	June 2, 2014 Notice of Allowance (excerpt from prosecution history of '438 patent)
AMG 1017	Declaration of Dr. DeForest McDuff, PhD (“McDuff Declaration”)
AMG 1018	2011 Zytiga® Approval Prescribing Information
AMG 1019	2015 Zytiga® Prescribing Information, Co-administration Brochure
AMG 1020	Harris <i>et al.</i> , “Low dose Ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer,” <i>The Journal of Urology</i> , volume 168:542-545 (August 2002)
AMG 1021	William Oh, “Secondary hormonal therapies in the treatment of prostate cancer,” <i>Urology</i> , volume 60:87-93 (Supplement 3A) (September 2002)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.